1. Home
  2. NVCR vs TSLX Comparison

NVCR vs TSLX Comparison

Compare NVCR & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TSLX
  • Stock Information
  • Founded
  • NVCR 2000
  • TSLX 2010
  • Country
  • NVCR Jersey
  • TSLX United States
  • Employees
  • NVCR N/A
  • TSLX N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TSLX Investment Managers
  • Sector
  • NVCR Health Care
  • TSLX Finance
  • Exchange
  • NVCR Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • NVCR 1.8B
  • TSLX 1.9B
  • IPO Year
  • NVCR 2015
  • TSLX 2014
  • Fundamental
  • Price
  • NVCR $17.49
  • TSLX $20.40
  • Analyst Decision
  • NVCR Buy
  • TSLX Buy
  • Analyst Count
  • NVCR 5
  • TSLX 7
  • Target Price
  • NVCR $26.60
  • TSLX $22.43
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • TSLX 231.8K
  • Earning Date
  • NVCR 10-30-2024
  • TSLX 11-05-2024
  • Dividend Yield
  • NVCR N/A
  • TSLX 11.58%
  • EPS Growth
  • NVCR N/A
  • TSLX 4.41
  • EPS
  • NVCR N/A
  • TSLX 2.36
  • Revenue
  • NVCR $549,964,000.00
  • TSLX $473,575,000.00
  • Revenue This Year
  • NVCR $16.23
  • TSLX $10.80
  • Revenue Next Year
  • NVCR $6.09
  • TSLX N/A
  • P/E Ratio
  • NVCR N/A
  • TSLX $8.64
  • Revenue Growth
  • NVCR 8.33
  • TSLX 23.94
  • 52 Week Low
  • NVCR $10.87
  • TSLX $19.33
  • 52 Week High
  • NVCR $24.74
  • TSLX $22.35
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 43.24
  • TSLX 45.10
  • Support Level
  • NVCR $15.61
  • TSLX $20.33
  • Resistance Level
  • NVCR $17.31
  • TSLX $20.81
  • Average True Range (ATR)
  • NVCR 1.29
  • TSLX 0.20
  • MACD
  • NVCR 0.05
  • TSLX -0.01
  • Stochastic Oscillator
  • NVCR 11.59
  • TSLX 23.81

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: